IL1R1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, in a mouse model of CML, IL-1R antagonists (IL-1Ra) in combination with nilotinib [96], a BCR-ABL tyrosine kinase inhibitor, reduced the number of leukemic cells in blood and bone marrow, as well as the self-renewal potential of LSCs significantly better than nilotinib therapy alone [97].